Literature DB >> 17966220

Use of lysophosphatidic acid in the management of benign and malignant ovarian tumors.

B Pozlep1, M Meleh, B Kobal, I Verdenik, J Osredkar, L Z Kralj, H Meden-Vrtovec.   

Abstract

OBJECTIVE: To establish whether LPA determination improves the differentiation of benign from malignant ovarian tumors.
METHODS: Total LPA and LPA species in the serum were determined using a novel method in 142 patients with ultrasound (US) suspecious ovarian tumors and in 78 healthy women. All women underwent determination of CA125 in the serum, a vaginal US examination and morphology scoring of the tumor.
RESULTS: The levels of total LPA and its species in women with ovarian tumors were significantly higher from those in healthy women (p < 0.001). No significant difference was found in the levels of total LPA or any of its species between the women with benign and those with malignant ovarian tumors.
CONCLUSIONS: Determination of serum LPA would be an appropriate test for ovarian tumor presence, especially in women of reproductive age. The method however does not differentiate benign from malignant ovarian tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17966220

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  6 in total

Review 1.  The human plasma lipidome.

Authors:  Oswald Quehenberger; Edward A Dennis
Journal:  N Engl J Med       Date:  2011-11-10       Impact factor: 91.245

2.  Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer.

Authors:  Tugan Bese; Merve Barbaros; Elif Baykara; Onur Guralp; Salih Cengiz; Fuat Demirkiran; Cevdet Sanioglu; Macit Arvas
Journal:  J Gynecol Oncol       Date:  2010-12-31       Impact factor: 4.401

3.  Lysophosphatidic acid (LPA)—a perspective marker in ovarian cancer.

Authors:  Iva Sedláková; Jaroslava Vávrová; Jindřich Tošner; Ladislav Hanousek
Journal:  Tumour Biol       Date:  2011-04

4.  An extremely simple method for extraction of lysophospholipids and phospholipids from blood samples.

Authors:  Zhenwen Zhao; Yan Xu
Journal:  J Lipid Res       Date:  2009-09-25       Impact factor: 5.922

5.  Plasma levels of lysophosphatidic acid in ovarian cancer versus controls: a meta-analysis.

Authors:  Yi-Yang Li; Wen-Chao Zhang; Jia-Ling Zhang; Chang-Jun Zheng; He Zhu; Hui-Mei Yu; Li-Mei Fan
Journal:  Lipids Health Dis       Date:  2015-07-15       Impact factor: 3.876

6.  Measurement of phospholipids may improve diagnostic accuracy in ovarian cancer.

Authors:  Lian Shan; Y Ann Chen; Lorelei Davis; Gang Han; Weiwei Zhu; Ashley D Molina; Hector Arango; James P LaPolla; Mitchell S Hoffman; Thomas Sellers; Tyler Kirby; Santo V Nicosia; Rebecca Sutphen
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.